Alumis (NASDAQ:ALMS) Director James Tananbaum Acquires 200,000 Shares

Alumis Inc. (NASDAQ:ALMS) Director James Tananbaum purchased 200,000 shares of the business’s stock in a transaction dated Monday, November 17th. The stock was purchased at an average price of $5.59 per share, for a total transaction of $1,118,000.00. Following the completion of the acquisition, the director owned 2,234,129 shares of the company’s stock, valued at approximately $12,488,781.11. This represents a 9.83% increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which is available at this link.

Alumis Trading Up 2.5%

Shares of ALMS stock traded up $0.16 on Wednesday, hitting $6.57. 1,624,729 shares of the stock were exchanged, compared to its average volume of 821,277. The firm has a market capitalization of $683.67 million, a P/E ratio of -1.62 and a beta of -1.33. Alumis Inc. has a fifty-two week low of $2.76 and a fifty-two week high of $10.49. The business has a 50-day moving average of $4.61 and a 200 day moving average of $4.23.

Alumis (NASDAQ:ALMS) last released its quarterly earnings results on Thursday, November 13th. The company reported ($1.06) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.92) by ($0.14). The business had revenue of $2.07 million during the quarter, compared to analysts’ expectations of $3.14 million. As a group, research analysts forecast that Alumis Inc. will post -8.51 EPS for the current fiscal year.

Wall Street Analyst Weigh In

ALMS has been the subject of several recent research reports. Wells Fargo & Company assumed coverage on shares of Alumis in a report on Friday, July 25th. They set an “overweight” rating and a $17.00 target price for the company. HC Wainwright restated a “buy” rating and set a $14.00 price objective on shares of Alumis in a research note on Thursday, August 14th. Morgan Stanley decreased their price objective on Alumis from $23.00 to $22.00 and set an “overweight” rating for the company in a report on Friday, August 15th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Alumis in a report on Thursday, November 13th. Finally, Wall Street Zen downgraded Alumis from a “hold” rating to a “sell” rating in a research note on Saturday. Six equities research analysts have rated the stock with a Buy rating and one has given a Sell rating to the stock. Based on data from MarketBeat, Alumis has an average rating of “Moderate Buy” and an average target price of $19.20.

Hedge Funds Weigh In On Alumis

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Corebridge Financial Inc. increased its holdings in shares of Alumis by 53.0% in the first quarter. Corebridge Financial Inc. now owns 10,658 shares of the company’s stock valued at $65,000 after purchasing an additional 3,693 shares during the last quarter. Los Angeles Capital Management LLC acquired a new stake in shares of Alumis during the 2nd quarter worth about $368,000. Credit Industriel ET Commercial boosted its holdings in shares of Alumis by 178.8% during the 2nd quarter. Credit Industriel ET Commercial now owns 387,002 shares of the company’s stock worth $1,161,000 after buying an additional 248,202 shares during the period. Blair William & Co. IL acquired a new position in Alumis in the 2nd quarter valued at about $200,000. Finally, Tybourne Capital Management HK Ltd. bought a new position in Alumis in the 2nd quarter valued at about $4,198,000.

About Alumis

Our mission is to significantly improve the lives of patients by replacing broad immunosuppression with targeted therapies. Our name, Alumis, captures our mission to enlighten immunology, and is inspired by the words “allumer”-French for illuminate-and “immunis”-Latin for the immune system. We are a clinical stage biopharmaceutical company with an initial focus on developing our two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001, a second-generation inhibitor that we are developing to maximize target inhibition and optimize tolerability, and A-005, a central nervous system (CNS) penetrant molecule.